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Abstract: Both caffeic acid and 3,4-dihydroxyphenyllactic acid (danshensu) are synthesized through
two distinct routs of the shikimic acid biosynthesis pathway. In many plants, especially the rosemary
and sage family of Lamiaceae, these two compounds are joined through an ester linkage to form
rosmarinic acid (RA). A further structural diversity of RA derivatives in some plants such as
Salvia miltiorrhiza Bunge is a form of RA dimer, salvianolic acid-B (SA-B), that further give rise
to diverse salvianolic acid derivatives. This review provides a comprehensive perspective on the
chemistry and pharmacology of these compounds related to their potential therapeutic applications
to dementia. The two common causes of dementia, Alzheimer’s disease (AD) and stroke, are
employed to scrutinize the effects of these compounds in vitro and in animal models of dementia.
Key pharmacological mechanisms beyond the common antioxidant and anti-inflammatory effects of
polyphenols are highlighted with emphasis given to amyloid beta (Aβ) pathologies among others
and neuronal regeneration from stem cells.
Keywords: Alzheimer’s disease; amyloid beta; caffeic acid; danshensu; dementia; neurodegeneration;
rosmarinic acid; salvianolic acids; tau protein
1. Introduction
Epidemiological and global impact analysis of dementia has been regularly updated by the World
Health Organization and various institutions associated with the disease such the Alzheimer’s societies.
According to the Alzheimer’s Disease International [1], dementia is one of the leading public health
priority with a global prevalence of 46.8 million that is also expected to double every 20 years or a
projection of around 131.5 million cases by 2050. The disease is associated with progressive cognitive
impairment and function requiring continuous care and often institutionalization.
Accounting for around 70% of all cases, the leading cause of dementia is Alzheimer’s disease
(AD) [1,2]. Most often presented as an age-related disease, the global prevalence of AD has seen rapid
increase in parallel with increased life expectancies resulting from progressive economic development.
The second most leading cause of dementia in the world is cerebrovascular disease (CVD) with up
to one third of stroke survivors are estimated to suffer from some form of dementia or post-stroke
dementia [3]. Mixed dementia is a case where AD and CVD occur together while numerous other
causes including long-term cognitive disorder associated with alcoholism [4], epilepsy [5], etc. have
been reported.
The lack of real progress in dementia therapy is evident from the existing therapeutic approaches
that all put their focus in reducing the progressive clinical symptoms instead of cure. Thus, a great deal
of global efforts has been placed to look for potential drugs from both synthetic and natural sources that
offer novel approaches or unique molecular targets. Beyond our own input in this search efforts, review
articles from our laboratories have scrutinized the anti-AD potential of numerous natural products in
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general [6] and specifically those belonging to the class of monoterpenes (e.g., the iridoids class) [7],
diterpenes [8] and flavonoids [9–13]. The other natural product that we highlighted as potential therapy
for dementia was caffeic acid along with its ester derivatives such as chlorogenic acid and caffeic
acid phenethyl ester [14]. The fairly few steps in the biosynthetic pathway of caffeic acid and related
compounds (see Figure 1) and its ubiquitous presence in our common food ingredients such as coffee,
cherries, apples and honey give us even more incentive to investigate these compounds as potential
leads. The present review is designed to investigate the molecular and gross pharmacological profile
related to dementia of compounds called salvianolic acids and rosmarinic acid (RA). Structurally, these
compounds are composed of caffeic acid (structure 12) and a related phenolic compound, danshensu
(3,4-dihydroxyphenyllactic acid, structure 14, Figure 1).
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Figure 1. Overview of the biosynthesis pathway of rosmarinic acid and related compounds in plants. 
4CL, hydroxycinnamate (or 4-coumaric acid) coenzyme A ligase; C4H, cinnamic acid 4-hydroxylase; 
HPPR, hydroxyphenylpyruvate reductase; PAL, phenylalanine ammonia-lyase; RAS, rosmarinic acid 
synthase; TAT, tyrosine aminotransferase. Compounds highlighted by red box are precursors of the 
salvianolic acids. Dashed arrows represent multi-step reactions. 
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Figure 1. Overview of the biosynthesis pathway of rosmarinic acid and related compounds in plants.
4CL, hydroxycinnamate (or 4-coumaric acid) coenzyme A ligase; C4H, cinnamic acid 4-hydroxylase;
HPPR, hydroxyphenylpyruvate reductase; PAL, phenylalanine ammonia-lyase; RAS, rosmarinic acid
synthase; TAT, tyrosine aminotransferase. Compounds highlighted by red box are precursors of the
salvianolic acids. Dashed arrows represent multi-step reactions.
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2. Natural Occurrence and Biosynthesis of Rosmarinic and Salvianolic Acids
Rosmarinic acid (RA, stricture 11, Figure 1) was first isolated from Rosmarinus officinalis and
characterized by Italian scientists in 1958 [15]. The natural distribution of RA has been widely reported.
In a review by Petersen and Simmonds [16], plants belonging to at least 10 families of the dicots and five
monocots were reported to synthesize RA. Members of the family Lamiaceae predominantly reported
as common herbal sources of RA include common sage (Salvia officinalis), peppermint (Mentha piperita),
thyme (Thymus vulgaris), lemon balm (Melissa officinalis) and Rosemary (R. officinalis). The phylogenic
relationship within the angiosperms with respect to RA biosynthesis as well as detailed prevalence in
the plant kingdom has been reviewed by Petersen et al. [17].
Petersen et al. [17] have also outlined the biosynthesis of RA and its significance from evolutionary
perspectives. They have shown the key enzymes involved in the biosynthesis machinery which by
and large is the common shikimic acid pathway involved in the flavonoids and many other phenolic
compounds’ synthesis in plants. The biosynthesis of RA involves two synthetic routes to yield the
two monomeric units, caffeic acid (12) and danshansu (14) that are both products of the shikimic
acid pathway. Without going into details, one can start these biosynthesis steps from the primary
metabolites, phenylalanine (1) and tyrosine (5, Figure 1). The deamination of phenylalanine through
the action of phenylalanine ammonia-lyase (PAL; E.C. 4.3.1.5) results in cinnamic acid (2). Further
catalysis by cinnamic acid 4-hydroxylase (cytochrome P450 monooxygenase cinnamate 4-hydroxylase
(CAH; E.C. 1.14.13.11) yields p-coumaric acid (or 4-coumaric acid, 3) that is widely distributed in
plants in various forms including the lingnins/lignans. The transformation of this compound by
hydroxycinnamate coenzyme A ligase (4CL; E.C. 6.2.1.12) yield 4-coumaroyl-CoA (4) that serves as a
precursor to flavonoids as well as RA (11) biosynthesis. In another route of biotransformation, tyrosine
aminotransferase (TAT; E.C. 2.6.1.5) acts as an entry point enzyme [18] and converts tyrosine (5)
to the phenylpyruvate derivative (6) that is reduced by the action of 4-hydroxyphenylpyruvate
reductase to give 4-hydroxyphenyllactic acid (7); a precursor of danshensu (14). The coupling of
compound 7 with 4-coumaroyl-CoA (4) is an esterification process catalyzed by rosmarinic acid
synthase (RAS). Oxidation of the aromatic rings can then proceed to yield various products including
RA (11) which carries a catechol functional group at both ring systems. This process, as outlined in
Figure 1 can take one step at a time in both rings leading to RA (11) and the presence of compounds
like isorinic acid (10) in nature shows this transition process. Hydroxylation at a specific C-3 position
of the aromatic skeleton to give these two intermediates have also been suggested: i.e., the existence
of 4-coumaroyl-4′-hydroxyphenyllactate 3/3′-hydroxylases and caffeoyl-4′-hydroxyphenyllactate
3′-hydroxylase enzymes in RA producing plants [17]. These two distinct routes of caffeic acid and
3,4-dihydroxyphenyllactic acid (danshensu) in rosmarinic acid synthesis has been confirmed through
numerous other studies since the 1970s in both plants and tissue culture studies [19,20]. Caffeic acid
also exist in a range of other metabolites such as esters and glycosidic forms. Of the biologically
significant caffeic acid derivatives are caffeic acid phenethyl ester and chlorogenic acid (13) and
other quinic acid derivatives that display a plethora of pharmacological effects including anti-AD
potential [14].
The other RA analogues are where the combination between caffeic acid (12, Figure 2) and danshensu
(14) occur via esterification at other sites. Classical examples are salvianolic acid H (SA-H, 15), I (SA-I,
16) and J (SA-J, 17). The major structural diversity of RA however comes when two units of RAs are
combined to form a compound as that represented by salvianolic acid B (SA-B, 19). This compound
appears to be a precursor to many related salvianolic acid derivatives and lithospermic acids (Figure 2).
The interconversion of these compounds has been studied by various authors. Li et al. [21] with
the review of previous studies have outlined degradation processes in plant tissues and aqueous
extracts where salvianolic acid A (SA-A, 22) is shown as the degradation product of SA-B among
others (Figure 2). Other studies have further shown that such transformation can readily takes place
under high temperature, high pressure and high humidity environments in aqueous media [22]. Today,
the acquisition of these compounds through total synthesis has become a common practice. Zheng et
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al. [23] have reported an 8-step synthesis of (+)-SA-A in a yield of 10.6%. Fortunately, this synthesis
process does not have to go through the long synthesis and degradation pathway of SA-B in living
system. Other synthesis approaches of salvianolic acid derivatives have also been postulated [24–26].
From the biological point of view, both for purified compounds and plant-based drug preparations,
SA-A and SA-B are the most important and hence emphasis is given in this review to highlight
their effect in the dementia brain. Both compounds are extracted from the root of Salvia miltiorrhiza
Bunge (Labiatae) (“Danshen” in Chinese, also known as Chinese sage): SA-B is the most abundant
and bioactive of the salvianolic acids [27]. The plant material is also extensively used not only in the
traditional Chinese medicine but as danshen dripping pills (a mixture of Salvia miltiorrhiza, notoginseng,
and borneol) which have been the subject of numerous clinical trials in recent years [28].
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Figure 2. The routes of synthesis of salvianolic acids and related compounds. Following the synthesis
of SA-B as dimeric RA, several oxidation and degradation reactions lead to diverse intermediates.
Note that various stereoisomeric derivatives can also be obtained.
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3. Salvianolic Acids and Dementia
3.1. In Vitro Effects
A summary of in vitro effects that attributes to the potential therapeutic effects of salvianolic
acid derivatives are shown in Table 1 [29–45]. By assessing the β-secretase (β-site amyloid precursor
protein (APP) cleaving enzyme or BACE1) and γ-secretase inhibitory activity, a selective effect against
BACE1 was demonstrated for SA-B [32]. Moreover, the direct interaction of the compound with the
catalytic center of the enzyme has been confirmed by docking experiments [32]. In SH-SY5Y-APPsw
cells, the Aβ40 and Aβ42 levels in culture media has been shown to be suppressed by SA-B [33].
While the protein expression of APP was not affected by SA-B, it has been shown to increase the
protein level expressions of “a disintegrin and metalloproteinase domain-containing protein 10”
(ADAM10) and secreted APP-α (sAPPα) concomitantly with the decreased protein expressions of
BACE1 and sAPPβ [33]. Such observation is in perfect agreement with the postulated mechanism of
action via inhibition of Aβ formation (Figure 3). The nonamyloidogenic pathway via the ADAM10
as a classic example of α-secretase within the Aβ domain that breaks down APP has now been well
established [46,47]. Interestingly, SA-B has been reported to increase the activity of α-secretase while
suppressing β-secretase. Hence, an augmented α-secretase pathway which is nonamyloidogenic and a
decrease in Aβ generation via amyloidogenic pathway was evident for SA-B (Figure 3).
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Figure 3. Anti-AD effect of salvianolic acids via Aβ formation. In the amyloidogenic pathway, APP
is first hydrolyzed by BACE1 and generates sAPPβ and C-terminal fragment-β of APP (CTF-β).
γ-Secretase further cleaves CTF-β to release APP intracellular domain (AICD) and Aβ, which aggregates to
form amyloid plaques. On the other hand, the nonamyloidogenic pathway involves the cleavage of
APP by α-secretase to release sAPPα and CTF-α. The latter is further cleaved by γ-secretase to yield
two fragments p3 and AICD. The effect of salvianolic acid via modulation of both pathways is shown.
Once Aβ is released, its self-aggregation to form fibrils is a prerequisite to induction of neurotoxicity
in the AD/dementia. Hence, compounds that either inhibit Aβ aggregation or those promoting
disaggregation of prefor ed fibrils are expected to hav nti-AD pote tial. The effect of SA-A in
reducing the m tal-induced aggregation by chelat ng metal ions; block the formation of intracellular
reactive oxygen species (iROS); i hibition of Aβ self-aggregation through binding to the C-terminus
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and hence stabilizing the helical conformations, was a finding by Cao et al. [31] worth mentioning.
The experiment by Durairajan et al. [38] also shed some light into the mechanism and level of potency
of SA-B in Aβ aggregation/disaggregation. They have shown that the compound can ameliorate fibril
aggregation with IC50 values between 1 and 5 µM while the destabilization effect on preformed Aβ1–40
fibril were similarly around 5 µM. This kind of activity in both the formation and the destabilization of
Aβ fibrils have demonstrated for other natural products such as curcumin that have been shown to
have a promise in AD [38].
Inhibition of cytotoxicity in neuronal cells induced by Aβ is another well-defined mechanism of
therapeutic agents. The effect of SA-B in PC12 cell death induced by Aβ25–35 [34,37] is a classic example
where cell survival coupled with reduction in ROS and intracellular Ca2+ (iCa2+) levels were observed.
Another cellular model was the SH-SY5Y cells cytotoxicity induced by Aβ1–40 where protective effect
was reported for SA-B. Worth noting is also the impressive level of potency where activity higher than
1 µM were shown to display cytoprotective effects.
When the pheochromocytoma cell line PC12 cells were exposed to H2O2-induced toxicity, SA-B
has been demonstrated to display protective effect at concentrations less than 10 µM [39]. In
addition to reducing the oxidative stress level as shown by the level of malondialdehyde (MDA)
level, increased antioxidant status (enhanced activities of superoxide dismutase (SOD), catalase (CAT)
and glutathione (GSH)-peroxidase (GPx)) was shown. Hence, the compound, beyond the known
direct radical scavenging effect against ROS, could enhance the antioxidant defence in neuronal
cells. The suppression on iCa2+ and caspase-3 activity is also in line with anti-apoptotic effect of
this compound in neuronal cells [39]. Another model of significance both in vitro and in vivo is the
oxygen-glucose deprivation/reperfusion (OGD/R) damage in neurons. The data by Wang et al. [30] on
primary rat cortical neurons showed that SA-B is cytoprotective primarily by increasing the activities
of antioxidant enzymes such as Mn-SOD, CAT and GPx. The mitochondrial mechanism of cell death
induced by the release of cytochrome c and induction of apoptosis was also demonstrated from
protective effects on mitochondrial membrane potential (∆Ψ(m)). Similar mechanisms and protective
effects were reported for salvianolic acid (undescribed) of commercial source [40].
Using the OGD/R model of cell damage in PC12 cells, Wang et al. [35] also showed the protective
effect of SA-B through anti-inflammatory mechanism. Hence, the common inflammatory target, NF-κB,
transcriptional activity and pro-inflammatory cytokine responses (IL-1β, IL-6, and TNF-α) have been
shown to be suppressed. The suppressive effect of SA-B in LPS-stimulated primary microglial cells is a
further example of anti-inflammatory effects [29]. This anti-inflammatory mechanism is elaborated in
great detail in Section 5.
Incredible level of attention has also been given in recent years to evaluate the potential of salvianolic
acids in promoting neuronal cell growth following ischemic or other forms of CNS pathology.
Interestingly, SA-B has been shown neuronal cell growth and differentiation from oligodendrocyte
precursors [36,41]. When bone marrow derived neural stem cells were treated with SA-B, an
enhanced potential for self-renewal and neuronal differentiation have been observed while cell survival,
including under oxidative stress condition induced by H2O2, were augmented by the compound [36].
Moreover, the induction of brain-derived neurotrophic factor (BDNF) production by SA-B in these
cells was in line with potential therapy not only to ameliorate the accelerated neuronal cell death in
dementia but also their recovery from stem cells [41]. In a similar experimental model, induction of
cellular proliferation and self-renewal maintenance by SA-B was coupled with upregulated expression
of nestin (marker protein of neuronal stem cells) via the PI3K/Akt pathway [42]. All these effects
also appeared to be mediated at concentrations from 5 to 50 µM and include promotion of neurite
outgrowth and their differentiation into neurons [44].
Most of the in vitro studies on neuronal cells so far appear to focus on SA-B, the most predominant
component of the natural salvianolic acids in the crude drug preparation of S. miltiorrhiza. An insight
into the synthetic source of compounds with similar mode of action has been the subject of many
studies too. For example, SMND-309 (Figure 4) is a caffeic acid dimer which has been shown to
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display similar effect in the OGD/R model in vitro (Table 1). Other effects of SA-B in vitro is associated
with increased antioxidant status in neuronal cells. Given the structural moieties including caffeic
acid and/or catechol functional groups, radical scavenging effects (e.g., [48]) is expected for these
compounds. The effect of SA-B in suppressing the cardiotoxicity of doxorubicin is also mediated
through antioxidant mechanism [49]. SA-B could also inhibit GSK3β by increasing the ratio of
pSer9-GSK3β to total GSK3β [33].
Table 1. In vitro neuroprotective effects of Salvianolic acids.
Compound Model Outcome Reference
SA-B LPS-stimulated primarymicroglial cells from mice
40 µM—Inhibit microglial activation; enhance neural precursor cell
proliferation, differentiation, and survival; inhibit NF-κB activation
along with ROS, NO, iNOS and cytokine (IL-1β, TNF-α and
IL-6) production.
[29,30]
SA-A SH-SY5Y cells treated with Aβ;Aβ aggregation assay
Cytoprotective; inhibit Aβ self-aggregation; disaggregates
pre-formed fibrils; reduce metal-induced aggregation through
chelating metal ions; reduce iROS.
[31]
SA-B
N2a-mouse and H4-human
neuroglioma cell lines
expressing SwedAPP cells
Decrease extracellular Aβ, soluble APPβ, and intracellular C-terminal
fragment β from APP; no effect on α-secretase and γ-secretase
activity and the levels of FL-APP; protein-docking model show
interactions with the BACE1 catalytic centre.
[32]
SA-B SH-SY5Y-APPsw cells
(25, 50, or 100 µM)—Reduce Aβ1–40 and Aβ1–42 level in culture
media; decrease the protein expressions of BACE1 and sAPPβ;
ADAM10 and sAPPα; inhibit GSK3β activity; attenuate oxidative
stress (enhance SOD and GPx activities).
[33]
SA-B Aβ25–35-treated PC12 cells
20 µM—Reverse the reduced expression level of BPRP; increase cell
viability; reduce ROS and iCa2+. [34]
SA-B
oxygen-glucose deprivation
and reoxygenation (OGD/R)
model in PC12 cells and
primary cortical neurons
Ameliorate NeuN protein release; inhibit the TLR4/MyD88/TRAF6
signaling pathway; inhibit NF-κB transcriptional activity and
pro-inflammatory cytokine (IL-1β, IL-6, and TNF-α).
[35]
SA-B
Primary culture of
oligodendrocyte precursor
cells from rats
20 µg/mL—promote differentiation. [36]
SA-B Aβ25–35-treated PC12 cells;enzyme assay
200 µg/mL—Revise cytotoxicity; Ca2+-intake and LDH release;
inhibit AChE.
[37]
SA-B
Aβ1–40 fibril formation and
destabilization; Aβ1–40-treated
SH-SY5Y cells
Inhibit fibril aggregation (IC50: 1.54–5.37 µM); destabilize preformed
Aβ fibril (IC50: 5.00–5.19 µM); inhibit cytotoxicity (above one µM).
[38]
SA-B H2O2-treated PC12 cells
(0.1–10 µM)—Pre-treatment—Improve cell survival and activities of
SOD, CAT and GPx; suppress MDA, LDH, iCa2+, caspase-3 activity
and apoptosis.
[39]
Salvianolic acid of
commercial
source—undescribed
Primary astrocytes from
rats—OGD-induced
mitochondria damage
Cytoprotective and reverse ∆Ψ(m) reduction [40]
SA-B Bone marrow derived neuralstem cells
Induce BDNF production; protect cells from H2O2 toxicity; promote
self-renewal and neuronal differentiation. [41]
SA-B Neural stem/progenitor cells 5–50 µM—Promote proliferation; up-regulate the expression of nestin;maintain self-renewal; effect mediated via PI3K/Akt pathway. [42]
SA-B OGD/RP-induced damage inprimary rat cortical neurons
Enhance cell viability and the activities of Mn-SOD, CAT and GPx;
elevate ∆Ψ(m) (p < 0.01) and depress the release of cytochrome c;
reverse neuronal morphological injury.
[43]
SA-B NSCs from mice
20 and 40 µg/mL—Increase the number of NSCs and their derivative
neurospheres; increase G2/S-phase cell population; promote neurite
outgrowth, proliferation and differentiation of NSCs.
[44]
SMND-309 (see
Figure 4)
Cultured rat cortical neuron
under OGD
3–100 µM—Increase cell survival rate, mitochondrial antioxidant
enzyme activities, respiratory enzymes activities, respiratory control
ratio and ATP content; decrease mitochondrial MDA content, LDH
release, iCa2+ level and caspase-3 activity.
[45]
Akt, protein kinase B; APP, Amyloid precursor protein; BACE1, beta-secretase 1; BDNF, brain-derived neurotrophic
factor; BPRP, brain–pancreas relative protein; CAT, catalase; GFAP, Glial fibrillary acidic protein; GPx,
glutathione peroxidase; Allograft inflammatory factor 1; iROS, intracellular reactive oxygen species; LDH,
lactate dehydrogenase; ∆Ψ(m) or mmp, mitochondrial membrane potential; MDA, malondialdehyde; MyD88,
myeloid differentiation primary response 88; NF-κB, nuclear factor κB; NSCs, neural stem cells; OGD/RP,
oxygen-glucose deprivation/reperfusion; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; sAPP, soluble
APP; SA-A, salvianolic acid A; SA-B, salvianolic acid B; SOD, superoxide dismutase; TLR4, toll-like receptor 4;
TRAF6, TNF receptor associated factor-6.
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SMDD (25) is a caffeic acid dimer that does not involve an ester bond but rather a C-C bridge. The C-5
chain derivative, compound 26, was found to have an optimum structure in antioxidant and Aβ
aggregation inhibition studies from studies on derivatives including C-3 to C-9 chain length, while
compound 27 was a prototype lead compound that does not have an ester linkage.
3.2. Salvianolic Acids Ameliorating Dementia in Animal Models
The various effects of salvianolic acids in AD and CVD animal models are summarized in
Table 2 [50–69]. The data by Shen t al. [52] in transgenic mice model show not only improvement of
learning and memory coupled with a reduction of Aβ level, but also various other metabolic markers.
This include the reduction in plasma low-densit lipoprotein cholesterol (LDL-C) level which appeared
to be positively correlated with Aβ1–42 level in the hippocampus. The positive correlation between Aβ
and LDL-C or negative relationship between Aβ and high density lipoprotein (HDL) is in line with
lipid lowering and cardiovascular protective effects [70,71]. Cholecalciferol (vitamin D) is expected
to have an enhanced function in Aβ clearance and its reduced level by salvianolic acids is expected
as Aβ level is normalized [51]. The data by Lee et al. [64] also provided the direct effect of SA-B in
Aβ-induced memory loss and inflammation in vivo.
The critical role of glial cells (primarily astrocytes and microglial cells) both in orchestrating the
Aβ induced inflammation and neurotoxicity in animals, and their protective effects in the Alzheimer’s
brain have been well established [72]. The crosstalk between this inflammatory cascade and ROS are
also evident as the latter could also augment the inflammatory response [73]. While glial cells are
involved in the clearance of Aβ, their overactivity in AD pathology is known to exacerbate AD and
hence they are serving as drug targets for therapeutic interventio . The data by Lee et al. [64] showing
a suppressive effect on cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) by SA-B
along with suppression of glial activation and memory improvement is a good set of in vivo evidence
of efficacy. One must also note the low dose employed (10 mg/kg) via the oral route of administration.
The direct effect of SA-B in AD model also came from studies where Aβ25–35 was injected into animals.
The resulting behavioural changes that could be ameliorated by SA-B appeared to be mediated via
the γ-aminobutyric acid (GABA)-ergic neurotransmitter system [66]. Through such mechanism, the
effect of SA-B in reversing the scopolamine and other drugs-induced cognitive impairments have been
established [66]. More specifically, SA-B (100 µM) was found to inhibit GABA-induced outward Cl−
currents in single hippocampal CA1 neuron [66]. In a similar model i mice, improvement of learning
and memory could be achieved by SA-B along with inhibition of glial activation and reduced level of
inflammatory markers such as iNOS and COX-2 expression levels as well as oxidative stress [64].
In view of the well-recognized pharmacological effects of salvianolic acids and the plant that
produce them, Salvia miltiorrhiza, several studies have been directing their focus on neuroprotective
effects in ischemia/reperfusion injury model in animals. The study by Fan et al. [50] highlighted
that the protective effect of SA-B was coupled with suppression of ROS and pro-inflammatory
cytokines (IL-1β, IL-6 and TNF-α). Through such action, the activation of glial cells could be
suppressed by this compound. The data by Zhang et al. [29] is also in agreement where microglial
activation or M1 microglial polarization toward M2 is targeted by SA-B (Table 2). Other studies
with the same anti-inflammatory mechanism for SA-B are also reported [60,62]; while others show
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augmented antioxidant defences such as SOD level/activity along with suppressed MDA or ROS
levels [61,69]. The ischemia/reperfusion (I/R) injury model study in rats also revealed that SA-B via
the intraperitoneal route not only suppress neuronal deficits at small doses but also ameliorate the
inflammatory components as evidenced from cytokines and adhesion molecules expression (Table 2).
A commercial product called “salvianolic acids for injections”, which predominantly contain SA-B,
has also been shown to have similar effect on neuroprotection and neuroinflammation in vivo [57].
Numerous other studies also reported the same findings for SA-B in this model [35,40]. More
importantly, memory functions in vascular dementia has been shown to be prevented by SA-B [42].
Table 2. In vivo neuroprotective effects of salvianolic acids.
Compound Model Outcome Reference
SA-B
Ischemia/reperfusion injury model
in mice—20, 40 or 60 mg/kg during
reperfusion
Neuroprotective—decrease ROS level; suppress the
expression of GFAP, Iba1, IL-1β, IL-6, TNF-α and
cleaved-caspase 3; inhibit astrocytes and
microglia overactivation.
[50]
Total salvianolic acid
(commercial source)
APPswe/PS1dE mice model—30
and 60 mg/kg for 14 weeks
Improve learning and memory; decrease the LDL-C and
cholesterol (higher dose) levels; decrease Aβ42 and Aβ40
levels in the hippocampus; increase glucose-6-phosphate,
sucrose-6-phosphate, sorbitol, ascorbate (higher dose); reduce
galactose and cholecalciferol in the hippocampus.
[51]
SA-A Subarachnoid hemorrhage model inrats—10 or 50 mg/kg, i.p.
Reduce the elevated levels of ROS and MDA; increase GPx
activity and GSH and BDNF in the cortex; decrease the release
of inflammation cytokines (TNF-α, IL-1β, IL-6, and IL-8);
reverse the decreased expression of Nrf2 and its downstream
targets (HO-1 and NQO-1); No effect on phosphorylation of
JNK but reversed the increased the phosphorylation of p38
MAPK and the decreased the phosphorylation of ERK.
[52]
SA-B
Vascular dementia model
(permanent bilateral common
carotid artery occlusion) in rats—
20 mg/kg, p.o. for 6 weeks
Reverse the reduced hippocampal IGF-1 levels; increase
phosphorylated-Akt level (Akt level not altered); inhibit
apoptosis of hippocampal neurons in CA1 region.
[53]
Total Salvianolic acid
Angiogenesis and long-term
neurological recovery after ischemic
stroke—permanent distal middle
cerebral artery occlusion—2 weeks
treatment model.
Enhanced post-stroke angiogenesis, pericytes and astrocytic
end feet covered ratio in the peri-infarct area; effects
dependent on activation of JAK2/STAT3 signaling pathway.
[54]
SA-B Chronic mild stress model inmice—20 mg/kg, i.p. for 3 weeks
Alter M1 microglial polarization toward M2 activation in the
hippocampus and cortex; alleviate neuronal deficits in
hippocampus; suppress pro-inflammatory markers (IL-1β,
IFN-γ, IL-6 and iNOS,); reverse the decrease in IL-4 in both
the hippocampus and the cortex; decrease the ratio of
(IL-6+-Iba1+)/Iba1+ cells, and increased the ratio of
(Arg-1+-Iba1+)/Iba1+ cells in hippocampus.
[29]
SA-B
Ischemia/reperfusion
(I/R—transient middle cerebral
artery occlusion) injury model in
rats—3, 6 or 12 mg/kg, i.p.
Decrease I/R-induced neurological deficits, plasma-soluble
P-selectin and soluble CD40 ligand, neuronal and DNA
damage in the hippocampal CA1 region and neural cell loss in
the ischemic core; inhibit mRNA and protein overexpression
in the penumbra cortex, including ICAM-1, IL-1β, IL-6, IL-8,
and MCP-1; reduce CD40 expression and NF-κB activation
[55]
Salvianolic Acids for
Injections—crude
mixture predominantly
SA-B. (commercial
source)
Ischemia/reperfusion or focal
cerebral ischemia model—23 or
46 mg/kg, i.p. for
4 days—pretreatment
Decrease neuroinflammation and infarction volume; inhibit
microglia activation along with TLR4/NF-κB-dependent
release of cytokines (IL-1β and IL-6).
[56]
SA-A
Focal cerebral ischemia (transit
middle cerebral artery occlusion
mice) model in mice—1 or 5 mg/kg,
i.p.
Ameliorate neuronal damage, neurological deficit and volume
of infarction; inhibit eNOS uncoupling and calpain proteolytic
activity; suppress peroxynitrite generation; increase AKT,
FKHR and ERK phosphorylation.
[57]
SA-A
Blood-spinal cord barrier (BSCB) in
spinal cord injury model in
rats—2.5, 5 or 10 mg/kg, i.p.
Neuroprotective effect via the expression of microRNA-101
(miR-101) under hypoxia; increase Nrf2 and HO-1 expression;
improve the recovery of neurological function.
[58]
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Table 2. Cont.
Compound Model Outcome Reference
SA-A Ischemic brain injury model inmice—50 and 100 µg/kg, i.v.
Neuroprotective and preserves the BBB; reduce oxidative
stress and apoptosis; promote endogenous neurogenesis;
reverse the expression levels of DCX and Bcl-2; suppress
NF-κB signaling and inflammation/nitrosative stress;
promote neurogenesis-related protein expression by
modulating GSK3β/Cdk5 activity; enhance the expression
levels of β-catenin/DCX and Bcl-2 for neuroprotection.
[59]
Commercially available
salvianolic
acid—undescribed
Cerebral infarction of I/R (MCAO
model)—10 mg/kg injection
Neuroprotection via antioxidant mechanism (increased SOD
and suppressed MDA levels); upregulate mtCx43 through
PI3K/AKT pathway.
[40]
SA-B MCAO model Prevent gross cerebral I/R injury. [35]
SA-B
Rat model of contusion by heavy
impact to induce spinal cord injury—
20 mg/kg, i.p. for 8 weeks
Increase myelin sheath and the number of regenerating axons;
restore neurological function; decrease caspase-3 expression in
the spinal cord.
[36]
SA-B MCAO model—25 mg/kgadministrated twice
Cerebral-protective effect—reduce infarct volume, lower brain
oedema; increase neurological scores; decrease TNF-α and
IL-1β levels in brain tissue; upregulate the expression of SIRT1
and Bcl-2; downregulate the expression of Ac-FOXO1 and Bax;
effects abolished by SIRT1 inhibitor (EX527).
[60]
SA-B
Mouse model of cerebral ischemia
and reperfusion injury (bilateral
carotid artery occlusion)—22.5
mg/kg
Decrease MDA content and NOS activity of the pallium;
increase SOD activity and the total antioxidant capability of
the pallium.
[61]
Total salvianolic acids
(commercial source)
MCAO model in rats—1.67 mg/kg,
i.p. administrated before
reperfusion
Attenuate I/R-induced microcirculatory disturbance and
neuron damage; activate AMPK, inhibit NADPH oxidase
subunits membrane translocation, suppress Akt
phosphorylation and PKC translocation.
[62]
SMND-309 (see Figure 4) MCAO model in the rats
Decrease infract volume; improve neurological function and
neuronal survival; promote angiogenesis by increasing the
levels of erythropoietin (EPO), erythropoietin receptor
(EPOR), phosphorylated JAK2 and STAT3, VEGF and VEGF
receptor 2 (Flk-1) in the brain.
[63]
SA-A Transgenic Caenorhabditis elegans Inhibit Aβ-induced paralysis. [31]
SA-B
Aβ25–35 injected
intracerebroventricularly in
mouse—10 mg/kg, p.o. for 7 days
Reverse memory impairment in the passive avoidance task;
reduce microglia and astrocytes activation; reduce iNOS and
COX-2 expression and TBRS level; restore ChAT and BDNF
protein levels.
[64]
SA-B
Traumatic brain injury in mice in
cortical impact model—25 mg/kg,
i.v.
Reduce brain oedema, lesion volume and motor functional
deficits; improve spatial learning and memory; inhibit the
neutrophil infiltration and microglial activation; suppress the
expression of pro-inflammatory cytokines (TNF-α and IL-1β)
and enhance the expression of anti-inflammatory cytokines
(IL-10 and TGF-β1) in brain tissues.
[65]
SA-B
Transient global ischemia in rats via
irreversibly vertebral arteries
occlusion—50 mg/kg, i.p. for
4 weeks
Protect learning and memory functions. [42]
SA-B
Drug-induced amnesic models
induced by scopolamine, diazepam,
muscimol, or Aβ25–35—10 mg/kg,
p.o.
Reverse cognitive impairments induced by scopolamine or
Aβ25–35; Effect via the GABAergic neurotransmitter system.
[66]
SMND-309 MCAO model in rats—2.5, 5 or 10mg/kg i.v. 3 and 12 h after occlusion
Decrease neurological deficit scores, reduce the number of
dead hippocampal neuronal cells, mitochondria swelling and
ROS production; mmp level and mitochondrial respiratory
chain complex activities; at 25.0 mg/kg—neuroprotective
effect still present 7 days after ischemia.
[67,68]
SA-B
Cerebral ischemia-reperfusion
model in rats via carotid artery
occlusion—10 mg/kg i.v.
Inhibit the decrease in SOD, GSH, and ATP levels and the
increase in MDA and lactic acid levels. [69]
AMPK, 5′ adenosine monophosphate-activated protein kinase; BBB, blood brain barrier; BSCB, blood-spinal cord
barrier; ChAT, choline acetyltransferase, COX-2, cyclooxygenase 2; ERK, mitogen-activated protein kinases; FOXO1,
Forkhead box protein O1 (FKHR) ; GFAP, glial fibrillary acidic protein; GSK, glycogen synthase kinase; HO-1, heme
oxygenase-1; Iba1, ionized calcium-binding adapter molecule 1; IGF-1, insulin-like growth factor-1; iNOS, inducible
nitric oxide synthase; Ionized calcium binding adaptor molecule 1; I/R, JAK2, Janus kinase 2, LDL, Low-density
lipoprotein; MCAO, Middle cerebral artery occlusion; mtCx43, mitochondrial connexin 43; NADPH, Nicotinamide
adenine dinucleotide phosphate (reduced form); Nrf2, erythroid 2-related factor 2; NOS, nitric oxide synthase;
NQO-1, NAD(P)H dehydrogenase [quinone] 1, PKC, protein kinase C; SIRT1, sirtuin (silent mating type information
regulation 2 homolog) 1; STAT3, Signal transducer and activator of transcription 3; TBRS, thiobarbituric acid reactive
substances; TGF-β1, Transforming growth factor beta 1.
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The effect of SA-B in other models include where direct physical damage to central neurons
is induced by heavy impact on the spinal cord. As shown by Zhu et al. [36], SA-B could promote
myelin sheath recovery and the number of regenerating axons while gross neurological function
was also recovered. These effect of SA-B could in part be explained by enhancing the expression of
anti-inflammatory cytokines (IL-10) while suppressing pro-inflammatory cytokines such as TNF-α
and IL-1β [67]. Such an effect was also shown to be linked with improvement in spatial learning and
memory [67].
Salvianolic acid A was also tested in cerebral ischemia model where neuroinflammation and
peroxynitrite (ONOO−) generation were shown to be suppressed [57]. Furthermore, upregulation
of the protein kinase B (PKB or Akt), Forkhead box protein O1 (FKHR or FOXO1) and
extracellular signal–regulated kinases (ERK) phosphorylation were reported in these experiments [57].
One remarkable observation was also the rather small intraperitoneal effective doses reported (1 mg
and 5 mg). The neuroprotective effect SA-A in blood-spinal cord barrier (BSCB) in spinal cord injury
model in rats has also demonstrated at small doses (2.5, 5 and10 mg/kg, i.p.) which were also
coupled with the expression of antioxidant marker proteins such as erythroid 2-related factor 2 (Nrf2)
and heme oxygenase-1 (HO-1) [58]. As with SA-B, the effect of SA-A on neuroprotection in vivo
through reduced oxidative stress and anti-inflammatory mechanisms including the suppression of key
inflammation cytokines (TNF-α, IL-1β, IL-6, and IL-8) have been demonstrated [52]. Moreover, the
compound reversed the increased level of phosphorylation of p38 mitogen-activated protein kinase
(MAPK) and the decreased level of phosphorylation of ERK induced by subarachnoid haemorrhage in
rats. This compound could also offer protective effect in ischemic brain injury model in mice when
administered at 50 and 100 µg/kg, i.v. [59]. The neuroprotective effect was also coupled with reduced
level of oxidative stress and anti-inflammatory effects via downregulating the NF-κB pathway [59].
In transgenic Caenorhabditis elegan model, Aβ-induced paralysis could also be inhibited by SA-A [31].
The effect of SA-A in brain protection from haemorrhage via suppression of oxidative stress and by
upregulating the Nrf2 antioxidant mechanism have been established [52]. Several other experiments
also showed that SA-A via activation of the Nrf2 signalling pathway ameliorate oxidative stress
under cellular and pathological conditions such as diabetes [74,75]. All the data presented in these
studies were consistent with key inflammatory cytokine mediators such as IL-1β, TNF-α and IL-6 were
suppressed suggesting the antiinflammatory effect of SA-A in the brain.
One common model of study frequently used to assess the central effect of salvianolic acids
is the vascular dementia model in animals via transient or permanent occlusion the carotid artery.
Ma et al. [53] have shown the potential of SA-B via the oral route of administration and a dose as
small as 20 mg/kg. Moreover, the induction of apoptosis in hippocampal neurons through this
model is inhibited by this drug via increasing the increased phosphorylated Akt level without altering
the protein level of Akt. Following ischemic stroke, the process of angiogenesis and long-term
neurological recovery have been studied by various authors. Li et al. [54], for example, have
shown that the total salvianolic acid drug preparation could enhance angiogenesis and neuronal
recovery through activation of the Janus kinase 2/signal transducer and activator of transcription 3
(JAK2/STAT3) signalling pathway. The synthetic drug SMND-309 that were shown some in vitro effect
in neuroprotection has also been shown to display neuroprotection in various in vivo models [64,67,68].
The role of these potential therapeutic agents in combination with other drugs is also worth mentioning.
For example, Yu et al. [76] have studied the combined effect of fluoxetine (20 mg/kg) and salvianolic
acid (40 mg/kg) in rats under chronic stress. Treatment for three weeks with a combined approach has
been shown to have a far better cognitive improvement in animals.
Various commercial products of these compounds are now available along with plant extracts that
often contain SA-B as predominant marker. For example, chromatographic trace of salvianolic acids
for injection as a commercial brand is predominantly SA-B (63.81%) containing trace amounts (5% or
less) of rosmarinic acid, salvianolic acid D and Y among other trace compounds [56]. The therapeutic
effect of crude drugs such as S. miltiorrhiza root preparations therefore need to be reflected in light of
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this reality. Most of the compounds such as SA-A and other derivatives are also active, however, and
are likely to contribute to the overall effect of the crude drugs.
4. Rosmarinus Acid (RA) in AD
Several in vitro and animal studies have shown the promise of RA in AD therapy. The experiment
by Taguchi et al. [77] using docking simulation and direct binding studies investigated the structural
features of RA that allowed it to directly interact with Aβ1–42. They have shown that the catechol
functional group on the caffeic acid side is an important structural feature for binding. On the
other hand, the ester-bond on the danshensu side which could be liable to breakdown in vivo could
be replaced by favourable chain-length substituents. Hence, they have shown two compounds
(26 and 27, see Figure 4) that are sufficiently antioxidant as assessed by xanthine oxidase and DPPH
radical-scavenging effects while at the same time showing good inhibition in Aβ1–42 aggregation.
The experiment by Espargaró et al. [78] also noted that the effect of RA in Aβ aggregation
was similar with other natural products known for such effects including melatonin, O-vanillin,
curcumin, apigenin and quercetin. In cultured PC12 cells treated with Aβ1–42, cytotoxicity coupled
with ROS formation, lipid peroxidation, DNA fragmentation, caspase-3 activation, and tau protein
hyperphosphorylation were all suppressed by RA (10 µM) [79]. On the other hand, evidence on the
potential anti-AD effect of RA through Aβ antagonism has also been demonstrated in vivo. Doses as
small as 0.25 mg/kg through oral route of administration for 14 days in mice were shown to ameliorate
the effect of intracerebroventricularly (i.c.v.) injected aggregated Aβ25–35 [80]. The favourable outcomes
include memory improvement along with decreased levels of NO and MDA levels in the brain,
kidney and the liver [80]. Oral administration of RA (50 mg/kg) for 60 days to ovariectomized rats
treated with D-galactose have also shown to restore the altered locomotor activity and cognitive
functions. Furthermore, other favourable effects in oxidative stress (e.g., lipid peroxidation levels)
and inflammation (COX-2 expression and PGE-2 levels) markers in brain tissue were observed [81].
In mice pre-injected (i.c.v.) with Aβ25–35, administration of a small dose of RA (0.25 mg/kg, i.p.) could
ameliorate the nitration of proteins and cognitive abnormalities [82].
Cornejo et al. [83] have done a pioneering experiment to show the role of RA on tau protein
precipitation and/or aggregation. They have shown that RA binding to tau protein in vitro leads
to a decrease in amide regions I and III suggesting that the compound inhibits β-sheet assembly.
Their molecular docking study further showed that RA binds to the steric zipper in the same
manner as orange G. Interestingly, these activities were demonstrated at effective concentration
of 10µM where both fibril formation and progression to oligomers are inhibited. In addition to the
in vitro data, the effect of RA as anti-AD agent in vivo through tau protein modulation has been
demonstrated [84]. As expected, they found that the level of phosphorylated tau protein increase
with age and chronic restraint stress (CRS) while inverse relationship was noted for the level of
chaperones expression (i.e., diminished with age or stress). CRS was also shown to suppress the
expression of Pin1, the peptidylprolyl cis/trans isomerase, in aging animals. All these parameters as
well as phosphorylated tau protein and insoluble phosphorylated tau protein formation induced by
stress/aging were shown to be revered by RA [84].
When tested at 10 µg/mL in vitro, RA has also been shown to display inhibitory effect against
acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) by 28% and 80% (IC50 = 6.59 µg/mL)
respectively [85]. Hence, it was more active in BChE than AChE. In vitro and ex vivo studies as well as
in silico docking studies by Demirezer et al. [86] also showed its AChE inhibitory activity along with
its known antioxidant capacity. The anti-AChE activity of RA was also investigate by Szwajgier [87] in
comparison with other phenolic acids where the order of potency was established in the following
order: homogentisic acid > 4-hydroxyphenylpyruvic acid > nordihydroguaiaretic acid > rosmarinic
acid > caffeic acid > gallic acid = chlorogenic acid > homovanillic acid > sinapic acid. Hence, RA appear
to be more potent than one of its monomer structural component, caffeic acid. The potential of RA in
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memory enhancement potentially through AChE and BChE inhibition have also been established in
many other studies [88,89].
5. Summary of Molecular Mechanisms That Attribute to the Dementia-Related Pharmacology of
Salvianolic and Rosmarinic Acids
To date, the therapeutic approaches of dementia are limited to disease management and bring
about some symptomatic relief. For the most prevalent form of dementia, AD, the pharmacological
approach of therapy is mainly driven by boosting cholinergic output. Classical examples are
cholinesterase inhibitors including donepezil, galantamine, and rivastigmine. The limited symptomatic
relief by using non-competitive N-methyl-D-aspartate receptor antagonists (e.g., memantine) have
also been clinically shown. It is also worth noting that attempts to find anti-AD therapy by abolishing
the Aβ loads has so far not been successful and approaches employing multiple targets or novel
mechanism are necessary (see Section 7). For detailed review on current therapeutic approaches,
readers are directed to review articles in this field [90,91]. The application of salvianolic acids and RA
appear to target not only biochemical mechanisms of AD but also CVD that is applicable to stroke.
A summary of these targets at molecular level is presented in the following sections.
5.1. Direct Effect on Aβ Formation and Aggregation, and ROS Generation
A quarter of a century has now elapsed since the Aβ hypothesis of AD has been postulated
to put Aβ formation and clearance dysfunction as the key pathological marker and/or therapeutic
target. Numerous small molecular weight compounds including some common food ingredients and
peptides modulators have also been identified and extensive review articles on the overall therapeutic
principle have been published (e.g., [92–94]). Interestingly, Aβ appear to be the main molecular target
for salvianolic acid and RA derivatives and the whole cascade of Aβ formation from APP, aggregation
and toxicity to neuronal cells are ameliorated by these compounds. With respect to Aβ formation,
the key amyloidogenic pathway enzyme, β-secretase (BACE1), has been reported to be suppressed
by SA-B and analogues while the nonamyloidogenic pathway enzyme ADAM10 (α-secretase) was
augmented (e.g., [33]). In animal model of AD, the level of Aβ has also been suppressed by these
potential therapeutic agents (e.g., [51]). Hence, one possible therapeutic target is Aβ formation as
depicted in Figure 3.
One of the hallmark of AD is the extracellular precipitation and accumulation of aggregated Aβ
that contributes to the observed biochemical and behavioral symptoms primarily through induction
of neuronal cell death. The role of metal ions such as copper, zinc and iron in orchestrating the Aβ
aggregation and toxicity through the generation of ROS have been well established. Hence one of the
therapeutic strategy in AD could come from overcoming the metal-induced Aβ pathology [95–97].
Hand-in-hand with the high level of transition metal ions associated with the Alzheimer’s brain,
ROS-induced neuronal damages has been shown to be correlated with Aβ pathology [98,99]. The
severity of AD pathology has also been shown to be inversely correlated with the level of antioxidant
defenses (both small molecular weight and proteins) in the brain [35–38]. Moreover, mitochondrial
dysfunction associated with ageing are the common source of ROS that contributes to AD severity [39].
Not surprisingly, salvianolic acids and RA that are efficient radical scavengers are also shown to boost
the antioxidant defenses in cellular and animal models (see Tables 1 and 2). They also ameliorate
the aggregation of Aβ that is a prerequisite to its toxicity in neuronal cells. One critical structural
feature for these compounds both in inhibition of Aβ aggregation and ROS-mediated toxicity is the
catechol functional moiety that comes in these compounds in good number (Figure 2). The association
between this functional group and anti-AD effects has been established in RA and analogues [77].
We have also shown that such functional group in phenolic acids as well as in the flavonoids skeleton
are optimized for numerous pharmacological effects linked to ROS, metal ions chelation and enzyme
inhibition [100–119]. Hence, the binding of SA-B with serum albumin was also suppressed in the
presence of Zn2+, Cu2+, Co2+, Ni2+ and Fe3+ suggesting direct interaction with the drug [120]. In a
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previous review from this laboratory, the coordination of metal ions with the catechol structural moiety
and such chelative effect as mechanism of biological activity in ROS generation and toxicity have been
outlined [14]. Interestingly, loss of memory function and learning by chronic metal (e.g., aluminum)
intoxication could be reversed by compounds such as caffeic acid [121]. Hence, the observed effect
of salvianolic acids and RA derivatives in dementia could be in part explained by the well-known
therapeutic strategy of ameliorating the ROS-Aβ-neurotoxicity crosstalk via redox metals (copper, zinc,
and iron) coordination [98,99,122–126].
Salvianolic acids and other RA derivatives also appear to target the inflammatory pathway
associated with the Alzheimer’s brain. The glial cells in the brain, primarily astrocytes and microglial
cells, are involved in the normal tissue defense and homeostasis mechanisms but their overactivation
has also been linked to AD pathology [127–131]. As shown in Tables 1 and 2, various inflammatory
mediators such as cytokines (TNF-α, IL-1β, and IL-6), COX and NOS as well as their products such
PGE-2 and NO, respectively have been shown to be suppressed by these compounds. More importantly,
key transcription factors such NF-κB that are associated with proinflammatory proteins expression are
targeted. Hence, the observed effect is in line with therapeutic strategies where TNF-α or NF-κB are
targeted in AD [132–135]. The crosstalk between inflammation and oxidative stress is also well-known
and key mediators such as Nrf-2 and HO-1 that are modulated by these drugs (Table 2) lay down the
foundation for possible molecular mechanisms of action.
The law level of Aβ observed after treatment with salvianolic acid derivatives could also be attributed
to increased clearance. More research is however required to show the contribution of such mechanism
of action to the overall anti-AD effects in vivo. Several terpenoids such as iridoids have been shown
to enhance Aβ by modulating the insulin degrading enzyme, the main extracellular Aβ degrading
protease enzyme [7]. The role of the microglia in Aβ clearance is also known (e.g., [136,137]) but
whether such mechanism makes significant contribution to the anti-AD effects of salvianolic acids and
RA derivatives remains to be established. The overall mechanism of these compounds in ameliorating
the Aβ toxicity through various mechanisms from direct effect on Aβ to general antioxidant and
anti-inflammatory effects is shown in Figure 5.
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Figure 5. Overview of the therapeutic potential of salvianolic acids and RA derivatives in dementia via
the various mechanisms of Aβ pathology. Mechanisms include inhibition of Aβ formation (1a), fibril
formation/elongation (1b), interaction with fibrils (1c) and aggregated plaques (1d), toxicity in neuronal
cells (2) and glial activation (3). The activation of glial cells to initiate inflammatory cascades (5) by
various agents including other toxicants such as ROS (4) could be in ibited t rough processes including
induction of ntioxidan def n es (6). Other established mechanisms are neuronal regeneration from
stem cells (7) and axonal and myelin sheath protection (8).
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5.2. Cholinesterase Inhibition
Given that AD is primarily linked to the loss of cholinergic neurons in the cortex, the major
therapeutic strategy is linked to enhancing the activity of the surviving neurons. Based on this
cholinergic hypothesis of the disease [138–141], AChE inhibition remains one of the major target
for anti-AD drugs. The various mechanisms listed above for salvianolic acids and derivatives that
augment the antioxidant status, ameliorate Aβ formation and toxicity, etc., inevitability lead to a
better cholinergic neurons profile in animal models (Table 2). Direct effect on the AChE has also been
reported in the various models (Tables 1 and 2) and should be listed as one mechanism of action for
these natural products.
5.3. Tau Protein Phosphorylation and Precipitation/Aggregation
One mechanism that does not appear to be well-established for salvianolic acids is modulation of
tau protein phosphorylation. The level of phosphorylation of this protein in neuronal cells through
regulation by various kinase and phosphatase enzymes is important for the normal function of the
protein in diverse physiological processes associated to the microtubules function. The intracellular
tangles as the hallmark of AD resulting from tau hyperphosphorylation is therefore an important
pharmacological target for potential drugs [142–144]. The inhibition of β-sheet formation and assembly
by RA has been, however, well documented [83,84]. Hence, both extracellular (Aβ) and intracellular
(tau) protein aggregation that are clinically seen as AD pathological markers are targeted by RA.
5.4. Neuronal Regeneration Mechanisms
While maintaining the viability of surviving neurons and increasing their activity by approaches
like AChE inhibition may offer some beneficial outcome in AD, the real breakthrough would be
if the lost neurons are replaced through regeneration or recovery from stem cells. As shown both
from cultured stem cells in vitro and animal experiments (Tables 1 and 2), this established mechanism
appears to be the most promising development in recent years for salvianolic acid derivatives [36,41,44].
The proliferation and differentiation of stem cells by this compound (Figure 5) is therefore one milestone
to register. This mechanism also coincides with one of the best future hope of AD therapy, stem cell
technology [145–147].
5.5. Cell Signalling
The MAPK include ERK, JNK, and p38 MAPK that are shown to play critical role in the regulation
of diverse cellular functions including cell proliferation, differentiation, survival, inflammation and
apoptosis [148]. Growth inhibition and induction of neuronal cell death can be induced by activation
and phosphorylation of the p38 MAPK and JNK pathways. Several internal and external signals that
induce oxidative stress (ROS) and induction of pro-inflammatory cytokines (e.g., TNF-α and IL-β) do
also mediate their cell death signalling via activation of p38 MAPK and JNK [148]. More specifically,
targeting the p38 MAPK pathway for the treatment of AD therapy has been advocated [149,150].
The role of these stress-associated kinases in tau protein phosphorylation and correlation with the
level of neuroinflammation has also been described [151] and it is generally accepted that these
kinases (JNK/p38) are considered as pathological markers of neuroinflammation in the Alzheimer’s
brain. On the other hand, the ERK signalling has been shown to negatively regulate the β-secretase
expression [152]. Activation of ERK and the PI3K signalling has also been shown to be associated with
neuronal survival. Hence, the neuroprotective effects of some flavonoids as anti-AD principles have
been shown to be partly mediated through activation of this pathways [153]. In this connection, various
studies have shown that the neuroprotective effects of salvianolic acids is mediated via modulating
the MAPK system (Tables 1 and 2). For example, SA-A was reported to suppress the phosphorylation
of p38 MAPK while increasing ERK phosphorylation [52,57]. The role of the GSK3β and PI3K/Akt
pathways in the various neuronal processes including tau protein phosphorylation has been extensively
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reviewed [7,150,154,155]. The above-mentioned pharmacological effects of salvianolic acids and RA
derivatives could thus be attributed to modulation of key signalling pathways.
6. Potential Drug Leads or Just Another Story of Diverse Pharmacological Effects
by Polyphenols?
The occurrence of caffeic acid in common food ingredients and their diverse pharmacological
effects have always been the subject of curiosity in both drug discovery and nutraceutical research.
Caffeic acid, most commonly appearing as quinic acid esters such as chlorogenic acid and dicaffeoyl
derivatives have also been shown to possess numerous pharmacological effects including antiviral
activity and many others far beyond their common antioxidant effects [156]. One advantage of
these compounds is their solubility in water and hence a better bioavailability through oral routs as
shown from their efficacy in animal studies (Table 2). Several bioavailability studies on salvianolic
acid derivatives have also been carried out to demonstrate their efficacy through an oral route.
Formulations specifically for injection route such as “salvianolic acid for injection” are also available
from which rosmarinic acid, SA-D, lithospermic acid and SA-B have been shown rapid distribution in
rat tissues [157]. Studies on SA-B following nasal administration has also shown that the compound
can reach the brain at a slower rate than the i.v. route but with prolonged and sustained rate [158].
Under I/R conditions, the cerbroprotective effect of SA-A has also been shown to be associated with
more access to the brain than in normal animals [159]. Furthermore, various studies highlighted in
Table 2 show that the effects of these compounds are also linked to restoring the BBB or BSCB that
are consistent with their (or their active metabolites) entry into the brain. Worth mentioning is also
their known prescribed effect as modulators of the cardiovascular system including stroke; the second
most risk factor for dementia in humans. Hence, these compounds indeed have far more potential
as therapeutic agents for dementia than just being seen as therapeutic leads. Moreover, the doses
that have shown neuroprotective effect in the various animal models of dementia have been very
impressive. From the traditional medicine point of view, the plant materials often in combination with
other herbs, as demonstrated in the Chinese practice, are utilized as systematic medicine. Another
pharmacological effect of these compounds worth mentioning is their potential application in drug
combination as demonstrated for fluoxetine-SA-A combination [76].
As always, the promise of compounds established through in vitro and animal studies must
be supported by clinical evidence to demonstrate the ultimate efficacy and safety for use in human
system. In this regard, the hard lesson learnt from Aβ clinical trial is worth mentioning. Of the
spectacular failure story reported recently was the discontinuation of the BACE inhibitor verubecestat
from the Phase III clinical trial by Merck [160]. Even though some clinical trials based on Aβ approach
are still ongoing (e.g., Eli Lilly), other setbacks from clinical trial such as bapineuzumab (Pfizer) and
solanezumab (Eli Lilly) are grim reminders that in vitro and animal studies of the Aβ inhibitors may not
correlate with efficacious under clinical conditions. According to ClinicalTrial.gov, danshen dripping
pills (Identifier no.: NCT02388984) is currently under Phase III clinical trial for non-proliferative
diabetic retinopathy. Clinical trial involving 200 participants for coronary heart disease and essential
hypertension is also in active phase study in China (Identifier no.: NCT01825759). Other clinical trial
mentioned in ClinicalTrial.gov are danshen extract for cardiovascular effects including dyslipidemias
and hypertension (Identifier no.: NCT01563770), and for angina and inflammation (Identifier
no.: NCT02870764). Fufangdanshen tablets that contain salvianolic acid along with several other
products such as ginsenosides are currently under clinical trial for vascular dementia (Identifier no.:
NCT01761227). While these clinical applications for various, but primarily cardiovascular diseases,
are important indicators for therapeutic application of salvianolic acid and plant containing such
compounds, direct efficacy under dementia conditions are yet to be demonstrated. Unlike the Aβ
drugs that failed under clinical trials, however, these compounds may have favourable outcome given
their diverse mechanisms listed throughout this review.
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7. Conclusions
Caffeic acid is a gift of nature that is commonly abundant in various food ingredients such as
coffee, honey and fruits and vegetables. The dimerization of caffeic acid or conjugation with another
phenolic acid, danshensu, through unique biosynthesis pathway in some plants such as sage have
paved the way to identify potential therapeutic agents for dementia. Such compounds belonging
to the salvianolic acid and RA derivatives have shown promising effect both in vitro and in vivo
at doses that are considered very potent. Beyond the common antioxidant and anti-inflammatory
mechanisms, specific effects on Aβ and tau protein pathologies coupled with potential recovery of
neuronal loss from stem cells have been documented. All these pieces of evidence thus warrant further
research, particularly clinical trials, that further validate their potential for treating dementia. The most
significant effect that needs highlighting as a concluding remark is their potential in both AD and CVD
cases of dementia.
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